Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aytu BioPharma Inc.

    NASDAQ: AYTU · Real-Time Price · USD
    2.00
    0.02 (1.01%)
    At close: Jun 24, 2025, 3:59 PM
    1.01%
    Bid 1.97
    Market Cap 12.34M
    Revenue (ttm) 69.22M
    Net Income (ttm) 1.64M
    EPS (ttm) -1.49
    PE Ratio (ttm) -1.34
    Forward PE 22.06
    Analyst n/a
    Ask 2.07
    Volume 185,074
    Avg. Volume (20D) 1,397,970
    Open 1.99
    Previous Close 1.98
    Day's Range 1.99 - 2.05
    52-Week Range 0.95 - 2.99
    Beta 0.05

    About AYTU

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AYTU
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +34.23%
    Aytu BioPharma shares are trading higher after the... Unlock content with Pro Subscription
    1 month ago
    +91.85%
    Aytu BioPharma shares are trading higher after the company reported better-than-expected Q3 financial results.
    news image

    1 day ago · accessnewswire.com

    Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

    Term loan maturity extended by 12 months to June 2029 Principal balance on term loan expanded to $13.0 million from $11.1 million currently Expanded revolving line of credit facility by $1.5 million E...

    news image

    2 weeks ago · accessnewswire.com

    Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

    Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepi...

    news image

    2 weeks ago · accessnewswire.com

    Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

    Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the ...

    news image

    2 weeks ago · accessnewswire.com

    Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

    Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA ...

    news image

    1 month ago · seekingalpha.com

    Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript

    Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan...

    news image

    1 month ago · accessnewswire.com

    Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

    Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of $3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to...

    news image

    1 month ago · accessnewswire.com

    Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

    DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its opera...

    news image

    2 months ago · accessnewswire.com

    Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

    Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on comm...

    Add to Watchlist